福元医药取得克立硼罗原料药上市申请批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the raw material drug Clobetasol, which is intended for the local treatment of mild to moderate atopic dermatitis in patients aged 2 years and older [1] Group 1 - The approval of Clobetasol will enrich the company's product line [1] - This development is expected to promote the company's sustainable, stable, and healthy growth [1]